



NOVEMBER 2017

PROVIDING INNOVATIVE SOLUTIONS TO THE PHARMACEUTICAL,
COSMETIC, SKINCARE, & CONSUMER PRODUCTS INDUSTRIES

OVERVIEW

1

Expanded the number of products licensed to P&G & in-market from one to three, across two brands

2

Finalised the second technology licensing agreement with all terms confirmed, awaiting only P&G's execution

3

P&G informed the Company this week that they are about to surpass 1,000,000 devices sold incorporating OBJ's magnetic micro-array technology.

4

Bodyguard – OBJ's manufacturing partner has produced the first pre-production samples which are being provided to several identified licensees for market evaluations

5

BodyGuard's Array/ HydroGel system being clinically evaluated at Curtin University trial to demonstrate its ability to provide superior delivery of partner drugs

6

Surface Hygiene technology being tested at a major FMCG company's laboratory, exploring application in two product categories

7

OBJ is committed to developing its own products containing its technologies & securing distributors

8

Additional product & licensing opportunities under development with new & existing partners in haircare, oral healthcare

9

Board under reconstruction with the addition of Steve Schapera & recruitment of a new Chairman underway

10

Well funded (>\$4.9m cash on hand)

CORPORATE INFORMATION (A\$)

KEY STATISTICS (08.11.2017)

ASX code	OBJ
Current share price	\$0.041
52 week high	\$0.081
52 week low	\$0.03
Shares on issue	~1,805m
Market capitalisation	~\$73m
Revenues (Half-year 2017)	\$1.43m
Cash (September 2017)	~\$4.9m

SHAREHOLDER BREAKDOWN

Top 5 shareholders	7%
Top 20 shareholders (inc top 5)	21%
Management	6%

BOARD OF DIRECTORS



MR GLYN DENISON

Non-Executive Chairman

Glyn has more than 30 years experience in international business development including 16 years in technology-intensive industries. Glyn has worked in Europe, China, South-East Asia & Australia & has extensive networks & contacts across Europe.



MR JEFFERY EDWARDS

Managing Director

Jeff is responsible for scientific & technology development of the Company as well as business development & the Company's international partnering programs.



DR CHRISTOPHER QUIRK

Non-Executive Director

Chris has been involved for 25 years in both teaching & research at the University of Western Australia & has worked both in the public & private sector as a consultant dermatologist. Dr Quirk is a Fellow of the Australasian College of Dermatologists & a member of the American Academy of Dermatology.



MR STEVEN SCHAPERA

Non-Executive Director

Steven has been a highly successful developer and distributor of cosmetics and his industry knowledge is a highly valued background as OBJ continues with the development of its own products.

NEW CHAIRMAN – the company has engaged an agency to secure a new Chairman to take the company to the next stage of its development

THE SCIENCE OF DIAMAGNETIC REPULSION



OBJ uses physical rather than chemical science to enhance product performance




Uses weak atomic force physics to control processing in drug & ingredient delivery that limit existing product efficacy & performance




OBJ Diamagnetic Repulsion Video – see www.obj.com.au to view online

TECHNOLOGY PLATFORMS



HISTORY WITH PROCTER & GAMBLE



PRODUCTS IN MARKET

Eye Wands




Magnetic Boosters

RNA Bundle
RNA Power Essence




Olay MagneMask

Jar Mask & Substrate
Mask products



FURTHER OBJ TECHNOLOGIES UNDER DEVELOPMENT



BODYGUARD PROGRESS

- First KneeGuard prototypes received from OBJ's manufacturing partner
- Potential marketing & distribution partner intends undertake & fund European consumer concept & clinical efficacy studies
- New Array Hydrogels technology being clinically trialed for the delivery of NSAID with the view to offering the world's first topical patch that is superior & safer than oral tablet forms



BODYGUARD

WORLD'S FIRST PRODUCT RANGE ENGINEERED
TO REVERSE THE EFFECT OF JOINT AGEING




**New Array/Hydrogel
hybrid system being
clinically trialled with a
view to opening new
opportunities in
pharmaceutical &
therapeutic markets**

**Secured
manufacturing
collaboration
with one of the
world's leading
sports tape
manufacturer**

**Discussions
well advanced
for distribution
with four major
FMCG &
pharmaceutical
companies**

BODYGUARD CLINICAL TRIAL RESULT



Clinically shown that Bodyguard & its proprietary drug-free formulation provided superior restoration of pain free mobility in cases of chronic osteoarthritis than topical non-steroidal, anti-inflammatory gel (Novartis Voltaren)

Clinically shown to preserve joint lubrication & energy absorption during exercise which translated into superior restoration of function & greater joint pain reduction than current analgesics

Now established that OBJ's technology platforms have increased the efficacy of a wide range of therapeutic agents including vitamins, minerals, electrolytes & supplements that are significantly limited by normal first pass metabolism. Discussions well advanced with Reckitt Benckiser, Pfizer & Beiersdorf

Product design now maturing for Kneeguard – other joint treatments commencing.

**Collaborative
Development
Agreement with
Japanese
manufacturing partner**

ADVANCED PACKAGING PROGRAMS



By incorporating new technologies directly into 3rd party packaging forms, OBJ provides partners with the ability to rapidly innovate new consumer focused product forms without the need for altered chemistry or regulatory approvals.

First two products from this program already committed to market launch.



SURFACE HYGIENE PROGRAM



- Surface disinfection is a global hygiene concern as bacteria become resistant to current disinfectants. OBJ surface hygiene technology has demonstrated a two fold increase in the kill rate of Golden Staph bacteria in University studies.
- Recent research findings has expanded the application fields for OBJ's technologies to include anti- fungal treatments.
- By increasing the penetration of common disinfectants into the surfaces that dominate hospitals & homes, OBJ can potentially deliver significantly increased hygiene outcomes without the need for harsher or more toxic chemistry.
- Multiple applications of OBJ technology being evaluated by one of the world's leading house-hold names in hygiene & cleaning products.

EXPANSION OF OBJ SKIN SCIENCE LAB



Laboratory resources comprise a Chief Scientist, Laboratory Manager, three highly skilled laboratory technicians & a Device Engineering Manager

The expansion programs to OBJ's respected skin science laboratory, undertaken earlier this year, has seen an increase in sample through-put capability of 300%, while maintaining the same staffing levels.

This is due to the two new mass spectrograph analysers installed as part of the expansion, which substantially reduced sample processing times over the previous HPLC based systems.

OBJ's skin science laboratory provides *in-vivo* & *ex-vivo* skin penetration evaluations for partner molecules using both human tape stripping & Franz diffusion cells using both human & artificial tissues.

HIGHLIGHTS



- Expanded the number of products licensed to P&G & in-market from one to three, across two brands
- Finalised the second technology licensing agreement with all terms confirmed, awaiting only P&G's execution
- P&G informed the Company this week that they are about to surpass 1,000,000 devices sold incorporating OBJ's magnetic micro-array technology.
- Bodyguard – OBJ's manufacturing partner has produced the first pre-production samples which are being provided to several identified licensees for market evaluations
- BodyGuard's Array/HydroGel system being clinically evaluated at Curtin University trial to demonstrate its ability to provide superior delivery of partner drugs
- Surface Hygiene technology being tested at a major FMCG company's laboratory, exploring application in two product categories
- Board under reconstruction with the addition of Steve Schapera & recruitment of a new Chairman underway



GLYN DENISON

Chairman

OBJ Limited

+61 8 9443 3011

JEFF EDWARDS

Founder & Managing Director

OBJ Limited

+61 8 9443 3011

MATTHEW WRIGHT

Investor Relations Consultant

NWR Communications

+61 (0) 451 896 420

matt@nwrcommunications.com.au

For more information visit:

www.obj.com.au